Literature DB >> 15204489

The health-related quality of life of people living with HIV/AIDS.

Janeen Hughes1, Jennifer Jelsma, Emilou Maclean, Marta Darder, Xolani Tinise.   

Abstract

PURPOSE: The prevalence of people living with HIV/AIDS (PLWA) in South Africa is estimated to be approximately 14.2% of the total population. In the absence of anti-retroviral therapy, PLWA are likely to experience a steady decline in function, as their immune systems become increasingly compromised. However, there is limited information available to determine the potential role of rehabilitation interventions in the management of PLWA in a resource-poor community.
SUBJECTS: Subjects were recruited from the population of beneficiaries of HIV/AIDS clinics run by Medecins Sans Frontières, which provides anti-retroviral therapy to PLWA within a resource poor community. The subjects, who were either in WHO Stage 3 or 4 of the disease and/or had a CD4 count of less than 200, were interviewed after enrolment on the anti-retroviral programme and before treatment was initiated. They were therefore not yet receiving anti-retroviral therapy. The control group consisted of a community sample randomly selected from the same area and who were in the same age range.
METHODS: As all participants were Xhosa speaking, the Xhosa version of the EQ-5D measure of HRQoL was utilized. ANALYSIS: The Mann-Whitney U-test was used to determine whether there was a difference in the rank ordering of responses to the five different domains of the EQ-5D and the Visual Analogue Scale of Health Status scores.
RESULTS: There were 123 and 108 subjects in the experimental and control groups, respectively. In the domain of mobility 30.9% of the subjects reported some or severe problems, compared to 14.8% of the control group (p < 0.001). The corresponding figures for the other domains were: self-care 14.8% and 4.6% (p = 0.016), usual activity 31.7% and 10.2% (p < 0.001), pain/discomfort 69.1% and 33.3% (p < 0.001) and anxiety/depression 33.4% and 24.2% (p = 0.123) for the experimental and control groups respectively. PLWA reported a VAS score of 60.4 (SD 22.1), which was significantly lower than that of the community sample (80.13, SD 20.4, p < 0.001).
CONCLUSION: Self-reporting indicates that Health Related Quality of Life is severely comprised in PLWA in Stages 3 and 4 and limitations in the four domains of mobility, usual activities, pain/discomfort and anxiety/depression constitute major problems for PLWA. There is an obvious need to provide a continuum of care, encompassing not only medical but also physical and mental rehabilitation services as well. In an area of high HIV prevalence, the provision of appropriate, multi-disciplinary health care services to PLWA presents a major challenge to the health services.

Entities:  

Mesh:

Year:  2004        PMID: 15204489     DOI: 10.1080/09638280410001662932

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  37 in total

Review 1.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

2.  Quality of life amongst young adults with stroke living in Kenya.

Authors:  G Muli; A Rhoda
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

3.  Mental health of carers of children affected by HIV attending community-based programmes in South Africa and Malawi.

Authors:  Sarah Skeen; Mark Tomlinson; Ana Macedo; Natasha Croome; Lorraine Sherr
Journal:  AIDS Care       Date:  2014-04-25

4.  The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study.

Authors:  Bjarne Robberstad; Jan Abel Olsen
Journal:  Cost Eff Resour Alloc       Date:  2010-04-16

Review 5.  The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.

Authors:  Mark J Siedner; Mwebesa B Bwana; Mahomed-Yunus S Moosa; Michelle Paul; Selvan Pillay; Suzanne McCluskey; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi
Journal:  HIV Clin Trials       Date:  2017-07-18

6.  Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria.

Authors:  Olurotimi Adejumo; Bibilola Oladeji; Onoja Akpa; Kay Malee; Olusegun Baiyewu; Adesola Ogunniyi; Scott Evans; Baiba Berzins; Babafemi Taiwo
Journal:  Int J STD AIDS       Date:  2015-09-18       Impact factor: 1.359

7.  Depression and HIV in Botswana: a population-based study on gender-specific socioeconomic and behavioral correlates.

Authors:  Reshma Gupta; Madhavi Dandu; Laura Packel; George Rutherford; Karen Leiter; Nthabiseng Phaladze; Fiona Percy-de Korte; Vincent Iacopino; Sheri D Weiser
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

8.  Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity.

Authors:  John R Keltner; Florin Vaida; Ronald J Ellis; Tobias Moeller-Bertram; Chelsea Fitzsimmons; Nichole A Duarte; Jessica Robinson-Papp; Robert H Dworkin; David B Clifford; Justin C McArthur; David M Simpson; Ann C Collier; Christina M Marra; J Hampton Atkinson; Igor Grant
Journal:  Psychosomatics       Date:  2012 Jul-Aug       Impact factor: 2.386

9.  The Prevalence of Common Mental Disorders Among South Africans Seeking HIV Testing.

Authors:  Ashraf Kagee; Wylene Saal; Laing De Villiers; Mpho Sefatsa; Jason Bantjes
Journal:  AIDS Behav       Date:  2017-06

10.  Social support as a protective factor for depression among women caring for children in HIV-endemic South Africa.

Authors:  Marisa Casale; Lauren Wild; Lucie Cluver; Caroline Kuo
Journal:  J Behav Med       Date:  2014-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.